Clinical Trials for Nasal Cancer

Currently registered clinical trials for Nasal Cancer from ClinicalTrials.gov. 25 recruiting, 50 total studies.

This content is for informational purposes only. Always consult a healthcare professional.

Source: ClinicalTrials.gov — U.S. National Library of Medicine — A database of privately and publicly funded clinical studies conducted around the world (U.S. National Library of Medicine, public domain).

This page lists clinical trials related to Nasal Cancer from the ClinicalTrials.gov database.

Trial Summary

  • Total studies: 50
  • Recruiting: 25
  • Active, not recruiting: 11
  • Completed: 7
  • Other: 7

Results are refreshed periodically and may not reflect the most current information available from ClinicalTrials.gov.

Recruiting Trials

NCT01137825 — Registry of Older Patients With Cancer

StatusRecruiting
PhaseN/A
SponsorUNC Lineberger Comprehensive Cancer Center
Enrollment3000
Study TypeOBSERVATIONAL
ConditionsChronic Myeloproliferative Disorders; Cognitive/Functional Effects; Leukemia; Lymphoma; Lymphoproliferative Disorder

RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future.

PURPOSE: This research study is gathering information from older patients with cancer into a registry.

StatusRecruiting
PhaseN/A
SponsorNational Cancer Institute (NCI)
Enrollment1500
Study TypeOBSERVATIONAL
ConditionsPleuropulmonary Blastoma; Cystic Nephroma; Ovarian Sertoli-Leydig Cell Tumors; Ocular Medulloepithelioma; Nasal Chondromesenchymal Hamartoma

Background:

- Pleuropulmonary blastoma (PPB) is a rare fast-growing lung tumor that is associated with other, rare tumor types. Most cases of PPB appear in children younger than 6 years of age. Recently, it has been shown that this condition can be inherited (e.g., mutation of the DICER1 gene). Researchers are studying both clinical and genetic aspects of this newly described condition. They …

NCT02012699 — Integrated Cancer Repository for Cancer Research

StatusRecruiting
PhaseN/A
SponsorUniversity of Nebraska
Enrollment999999
Study TypeOBSERVATIONAL
ConditionsPancreatic Cancer; Thyroid Cancer; Lung Cancer; Esophageal Cancer; Thymus Cancer

The iCaRe2 is a multi-institutional resource created and maintained by the Fred & Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and …

NCT03493425 — Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

StatusRecruiting
PhasePhase 2
SponsorECOG-ACRIN Cancer Research Group
Enrollment82
Study TypeINTERVENTIONAL
ConditionsStage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7
Interventions; ;

This randomized phase II trial studies how well chemotherapy before surgery and radiation therapy works compared to surgery and radiation therapy alone in treating patients with nasal and paranasal sinus cancer that can be removed by surgery. Drugs used in chemotherapy, such as docetaxel, cisplatin, and carboplatin work in different ways to stop the growth of tumor cells, either by killing the …

NCT04288726 — Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

StatusRecruiting
PhasePhase 1
SponsorBaylor College of Medicine
Enrollment18
Study TypeINTERVENTIONAL
ConditionsExtranodal Natural Killer/T-Cell Lymphoma, Nasal Type; Classical Hodgkin Lymphoma
Interventions

This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK/TL) or classical Hodgkin lymphoma (cHL) (hereafter these 3 diseases will be referred to as lymphoma). Patients lymphoma has come back or not gone away after treatment. Because there is no standard treatment for the patients cancer at this time or because the currently used t…

NCT04870762 — Customized 3D Printed Oral Stents During Head and Neck Radiotherapy

StatusRecruiting
PhasePhase 2
SponsorM.D. Anderson Cancer Center
Enrollment119
Study TypeINTERVENTIONAL
ConditionsHead and Neck Carcinoma; Malignant Parotid Gland Neoplasm; Maxillary Sinus Carcinoma; Nasal Cavity Carcinoma; Oral Cavity Carcinoma
Interventions;

This clinical trial studies the effect of customized 3 dimensional (3D) printed oral tents on patients with head and neck cancer who are receiving radiotherapy. Oral stents are made from the impression of patients’ mouth and cover patients’ teeth and gums during radiation therapy. A customized, 3D-printed oral stent may help to reduce mouth blisters and/or sores that may develop in patients whi…

NCT05027633 — Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)

StatusRecruiting
PhasePhase 2
SponsorM.D. Anderson Cancer Center
Enrollment35
Study TypeINTERVENTIONAL
ConditionsSquamous Cell Carcinoma; the Nasal Cavity; Paranasal Sinuses
Interventions; ;

This is a single arm phase II study that will evaluate the combination of pembrolizumab, docetaxel, and cisplatin or carboplatin (PDC) as single treatment modality in patients with stage II-IVb (T2-4, any N, M0) squamous cell carcinoma of the nasal cavity/paranasal sinuses (PNS SCC).

NCT05607888 — Prospective Study of Sinonasal and Skull-base Tumours Management

StatusRecruiting
PhaseN/A
SponsorUniversity Medical Centre Ljubljana
Enrollment120
Study TypeOBSERVATIONAL
ConditionsNasal Neoplasm; Nasal Neoplasm Benign; Skull Base Neoplasms; Skull Base Osteomyelitis; Sinonasal Disorder

This observational prospective clinical study aims to describe the epidemiology, management and outcome of patients with sinonasal and skull-base pathology (tumours and diseases with malignant clinical characteristics) in a tertiary otorhinolaryngology referral centre. The main questions it aims to answer are:

  • what is the caseload of patients with the included pathology in our centre
  • what …

NCT05483374 — The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers

StatusRecruiting
PhaseN/A
SponsorFondazione IRCCS Istituto Nazionale dei Tumori, Milano
Enrollment13600
Study TypeOBSERVATIONAL
ConditionsHead and Neck Cancer; Nasopharynx Cancer; Nasal Cavity and Paranasal Sinus Cancer; Salivary Gland Cancer; Middle Ear Carcinoma
Interventions

Cancer care for head and neck cancers is multidisciplinary and complex and knowledge on the rare ones is limited. There is a wide consensus that to support clinical research on rare cancers, clinical registries should be developed within networks specializing in rare cancers. Our hypothesis is that our head and neck cancer registry established in the framework of the European reference network …

NCT04755205 — A Natural History Study of Children and Adults With Olfactory Neuroblastoma

StatusRecruiting
PhaseN/A
SponsorNational Cancer Institute (NCI)
Enrollment525
Study TypeOBSERVATIONAL
ConditionsOlfactory Neuroblastoma; Esthesioneuroblastoma

Background:

Olfactory neuroblastoma (ONB) is a rare cancer. It grows from tissue in the upper part of the nose cavity, related to the sense of smell and can affect a person s sense of smell. Researchers want to better understand the health problems of people with ONB. This may help them design better treatment and supportive care studies.

Objective:

To better understand ONB-the course of the…

NCT05475925 — A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

StatusRecruiting
PhasePhase 1 / Phase 2
SponsorDren Bio
Enrollment200
Study TypeINTERVENTIONAL
ConditionsLGLL - Large Granular Lymphocytic Leukemia; Primary Cutaneous Gamma-Delta T-Cell Lymphoma; Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma; Hepatosplenic T-cell Lymphoma; Subcutaneous Panniculitis-Like T-Cell Lymphoma
Interventions

This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas

NCT05172245 — Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

StatusRecruiting
PhasePhase 1
SponsorNational Cancer Institute (NCI)
Enrollment46
Study TypeINTERVENTIONAL
ConditionsClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Head and Neck Carcinoma of Unknown Primary; Locally Advanced Head and Neck Squamous Cell Carcinoma; Locally Advanced Hypopharyngeal Squamous Cell Carcinoma; Locally Advanced Laryngeal Squamous Cell Carcinoma
Interventions; ;

This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach using chemotherapy together with radiation therapy (“chemo-radiation”) in patients with head and neck cancer. Ipatasertib is in a class of medications called protein kinase B (AKT) inhibitors. It may stop the growth of tumor cells and may kill them. Cisplatin, which is a chemothe…

NCT05978141 — A Registry for People With T-cell Lymphoma

StatusRecruiting
PhaseN/A
SponsorMemorial Sloan Kettering Cancer Center
Enrollment1000
Study TypeOBSERVATIONAL
ConditionsT-cell Lymphoma; NK-Cell Lymphoma; T-cell Prolymphocytic Leukemia; T-cell Large Granular Lymphocytic Leukemia; Chronic Lymphoproliferative Disorder of NK Cells
Interventions

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

NCT05898074 — Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery

StatusRecruiting
PhaseN/A
SponsorIndiana University
Enrollment30
Study TypeINTERVENTIONAL
ConditionsSkull Base Neoplasms; Cerebrospinal Fluid Leakage; Nasal; Hypertrophy, Mucous Membrane (Septum)
Interventions;

The purpose of this study is to specifically evaluate the effectiveness of PuraGel, a RADA16 polypeptide hydrogel, in expediting post-operative healing and re-mucosalization of the nasoseptal flap harvest site during endoscopic skull base surgery and the impact on patient and sinonasal morbidity.

NCT05943119 — Phase II Study of Intensity Modulated Radiotherapy in Dose Painting for Sinus Carcinomas After Endoscopic Surgery

StatusRecruiting
PhasePhase 2
SponsorCentre Francois Baclesse
Enrollment52
Study TypeINTERVENTIONAL
ConditionsTumor, Solid
Interventions;

The patient is randomized to one of the following groups:

  • Experimental group: Radiotherapy in painting dose on histoscannographic mapping
  • Control group: standard pan-sinus radiotherapy

NCT06867289 — Study of the Efficacy of Moderate Sedation With Intra-NAsal Dexmedetomidine Monitored by EEG MOnitoring

StatusRecruiting
PhaseN/A
SponsorCentre Hospitalier Régional Metz-Thionville
Enrollment50
Study TypeINTERVENTIONAL
ConditionsProcedural Sedation and Analgesia; Pediatric ALL
Interventions

This is a prospective, monocentric diagnostic study aiming to evaluate whether a sedation score obtained by a per-procedural electroencephalogram (EEG), the PSI score, could identify patients for whom a 2 μg/kg dose of DEX would not be sufficient for the successful performance of cerebral NMRI, and who could therefore benefit from a higher dosage of DEX (4 μg/kg).

NCT07063212 — A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

StatusRecruiting
PhasePhase 2
SponsorMemorial Sloan Kettering Cancer Center
Enrollment40
Study TypeINTERVENTIONAL
ConditionsSquamous Cell Carcinoma of Head and Neck; Sinus Cancer; Nasal Cavity Cancer; Oral Cavity Cancer; Oropharynx Cancer
Interventions;

The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).

NCT06618703 — Brain Irradiation for Childhood Cancer - Endocrine Monitoring During the First Years

StatusRecruiting
PhaseN/A
SponsorUniversity Hospital, Angers
Enrollment230
Study TypeINTERVENTIONAL
ConditionsEndocrine; Deficiency; Hypothalamo-Pituitary Disorder; Radiotherapy Side Effect
Interventions

BICHE- 1: Brain Irradiation for Childhood cancer - Endocrine monitoring during the first five years is a study of endocrine monitoring after cerebral radiotherapy.

The study concerns patients in remission at the end of oncological treatment aged between 4 and 18 years at the time of inclusion and who have had radiotherapy before the age of 16, irradiating all or part of the brain, with a delay…

NCT07218601 — Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer

StatusRecruiting
PhasePhase 2
SponsorMemorial Sloan Kettering Cancer Center
Enrollment60
Study TypeINTERVENTIONAL
ConditionsNon-Small Cell Lung Cancer
Interventions;

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure changes in certain chemicals in the breath before and after standard neoadjuvant therapy in people with NSCLC.

NCT07175155 — Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients

StatusRecruiting
PhaseN/A
SponsorZhejiang University
Enrollment410
Study TypeINTERVENTIONAL
ConditionsHypoxemia; Esophageal Cancer; Morbidly Obese Patients; Gastric Cancer
Interventions;

Hypoxaemia during sedated gastrointestinal endoscopy exceeds 40 % in morbidly obese (BMI ≥ 35 kg m-²) patients. High-flow nasal cannula alone often fails because of persistent airway collapse. A recent innovation in this domain is the COMBO Endoscopy Oropharyngeal Airway-a multifaceted device that encompasses capnography monitoring, bite block , oxygenation support, and oropharyngeal airway man…

NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients

StatusRecruiting
PhaseN/A
SponsorZhejiang University
Enrollment600
Study TypeINTERVENTIONAL
ConditionsHypoxia; Esophageal Cancer; Gastric Cancer (Diagnosis); Obstructive Sleep Apnea (OSA)
Interventions;

Hypoxia represents the most frequent adverse event during propofol-sedated gastrointestinal endoscopy. The STOP-BANG questionnaire serves as a widely adopted, straightforward tool for screening obstructive sleep apnea (OSA) risk, with a score ≥5 identifying high-risk OSA patients who are particularly susceptible to hypoxia under sedation. Although preliminary research from our team suggests tha…

NCT07257094 — Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Rehabilitation Following Nasal Skin Cancer

StatusRecruiting
PhaseN/A
SponsorHôpital NOVO
Enrollment346
Study TypeOBSERVATIONAL
ConditionsCarcinoma
Interventions;

This study aims to validate a French version of the Nasal Reconstruction FACE-Q questionnaire for patients who have undergone nasal reconstruction or prosthetic rehabilitation after surgery for nasal skin cancer. The questionnaire evaluates appearance, quality of life, and possible side effects related to the reconstruction.

The investigators hypothesize that the validated French version will …

NCT07615036 — AP-NOSES: A Prospective Multicentre Registry of Natural Orifice Specimen Extraction in Minimally Invasive Colorectal Surgery

StatusRecruiting
PhaseN/A
SponsorSingapore General Hospital
Enrollment800
Study TypeOBSERVATIONAL
ConditionsColorectal Neoplasms; Incisional Hernia
Interventions;

Natural orifice specimen extraction (NOSE) is a minimally invasive colorectal surgical technique in which the surgical specimen is removed through a natural orifice, including transanal or transvaginal routes, thereby avoiding an abdominal extraction incision. Observational studies suggest that NOSE may reduce wound-related morbidity and improve postoperative recovery, but prospective multicent…

NCT06980038 — Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

StatusRecruiting
PhasePhase 2
SponsorNational Cancer Institute (NCI)
Enrollment44
Study TypeINTERVENTIONAL
ConditionsHead and Neck Squamous Cell Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Nasal Cavity Squamous Cell Carcinoma; Oral Cavity Squamous Cell Carcinoma
Interventions; ;

This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. CDX-1140 is a monoclonal ant…

NCT07628738 — A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy

StatusRecruiting
PhasePhase 2
SponsorRuijin Hospital
Enrollment39
Study TypeINTERVENTIONAL
ConditionsLymphoma (Non-Hodgkin’s Lymphoma)
Interventions

This study is designed to evaluate the efficacy and safety of reduced-intensity radiotherapy for stage I/II low-risk nasal-type NK/T-cell lymphoma that has achieved complete remission after chemotherapy.

Active, Not Recruiting

NCT00544115 — Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

StatusActive, not recruiting
PhasePhase 2
SponsorCity of Hope Medical Center
Enrollment260
Study TypeINTERVENTIONAL
ConditionsChronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm
Interventions; ;

RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient’s immune system from rejecting the donor’s stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient’s bone marrow make stem cells, red blood cells, white blood…

NCT00336063 — Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

StatusActive, not recruiting
PhasePhase 1
SponsorNational Cancer Institute (NCI)
Enrollment18
Study TypeINTERVENTIONAL
ConditionsAdult Nasal Type Extranodal NK/T-Cell Lymphoma; Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Recurrent Nasopharyngeal Undifferentiated Carcinoma; Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7; Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7
Interventions; ;

This phase I trial studies the side effects and best dose of vorinostat when given together with azacitidine in treating patients with nasopharyngeal cancer or nasal natural killer T-cell lymphoma that has recurred (come back) at or near the same place as the original (primary) tumor, usually after a period of time during which the cancer could not be detected or has spread to other parts of th…

NCT00707473 — Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

StatusActive, not recruiting
PhasePhase 2
SponsorM.D. Anderson Cancer Center
Enrollment31
Study TypeINTERVENTIONAL
ConditionsLocally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma; Sinonasal Undifferentiated Carcinoma; Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8; Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC v8
Interventions; ;

This phase II trial studies how well docetaxel, cisplatin and fluorouracil work in treating patients with previously untreated stage II-IV nasal cavity and/or paranasal sinus cancer. Drugs used in chemotherapy, such as docetaxel, cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them …

NCT01787409 — Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

StatusActive, not recruiting
PhaseN/A
SponsorMayo Clinic
Enrollment565
Study TypeINTERVENTIONAL
ConditionsAggressive Non-Hodgkin Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-Cell Lymphoma; Chronic Lymphocytic Leukemia; Diffuse Large B-Cell Lymphoma
Interventions;

This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in patients with cancer who are vitamin D insufficient.

NCT02106988 — Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

StatusActive, not recruiting
PhasePhase 2
SponsorM.D. Anderson Cancer Center
Enrollment26
Study TypeINTERVENTIONAL
ConditionsLymphoma
Interventions; ;

The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control Stage 1 and/or 2 NK cell lymphoma. The safety of the radiation and chemotherapy combination will also be studied.

This is an investigational study. Radiation and chemotherapy are FDA approved and commercially available for patients with Stage 1 and/or 2 NK cell lymphoma. The combination …

NCT02834013 — Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

StatusActive, not recruiting
PhasePhase 2
SponsorNational Cancer Institute (NCI)
Enrollment798
Study TypeINTERVENTIONAL
ConditionsAcinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortical Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma
Interventions; ;

This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

This trial enrolls participants for the following cohorts based on condition:

  1. Epithelial tumors of na…

NCT04414163 — A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

StatusActive, not recruiting
PhasePhase 2
SponsorImmuneOncia Therapeutics Inc.
Enrollment23
Study TypeINTERVENTIONAL
ConditionsExtranodal NK/T-cell Lymphoma, Nasal Type; Extranodal NK/T-cell Lymphoma
Interventions

This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type

NCT04734145 — Using e-Nose Technology to Identify Early Lung Cancer

StatusActive, not recruiting
PhaseN/A
SponsorMemorial Sloan Kettering Cancer Center
Enrollment119
Study TypeOBSERVATIONAL
ConditionsLung; Node; Lung Cancer
Interventions

The purpose of this study is to test the ability of a new technology called breathprinting, or electronic nose (e-nose), to detect early-stage lung cancer. Additionally, researchers also want to see if the e-nose technology is more effective at diagnosing lung cancer if the tumor size is larger.

NCT05075980 — Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study

StatusActive, not recruiting
PhasePhase 2
SponsorMayo Clinic
Enrollment174
Study TypeINTERVENTIONAL
ConditionsHead and Neck Carcinoma; Head and Neck Carcinoma of Unknown Primary; Hypopharyngeal Carcinoma; Laryngeal Carcinoma; Metastatic Malignant Neoplasm in the Lymph Nodes
Interventions; ;

This clinical trial studies how well intensity modulated proton therapy (IMPT) or intensity modulated X-ray (radiation) therapy (IMRT) works after surgery in treating patients with head and neck cancer. IMPT is a type of radiation therapy that allows for the most accurate application of proton radiation to the tumor and has the potential to reduce treatment-related side effects. IMRT is a type …

NCT05063552 — Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

StatusActive, not recruiting
PhasePhase 2 / Phase 3
SponsorNational Cancer Institute (NCI)
Enrollment430
Study TypeINTERVENTIONAL
ConditionsClinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Hypopharyngeal Squamous Cell Carcinoma; Metastatic Laryngeal Squamous Cell Carcinoma; Metastatic Lip and Oral Cavity Carcinoma
Interventions; ;

This phase II/III compares the standard therapy (chemotherapy plus cetuximab) versus adding bevacizumab to standard chemotherapy, versus combination of just bevacizumab and atezolizumab in treating patients with head and neck cancer that has spread to other places in the body (metastatic or advanced stage) or has come back after prior treatment (recurrent). Immunotherapy with monoclonal antibod…

NCT06035497 — A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

StatusActive, not recruiting
PhasePhase 1 / Phase 2
SponsorBristol-Myers Squibb
Enrollment85
Study TypeINTERVENTIONAL
ConditionsRelapsed or Refractory T-cell Lymphomas
Interventions

The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 (Golcadomide) in participants with relapsed or refractory T-cell lymphomas in Japan (GOLSEEK-3).

Not Yet Recruiting

NCT07512466 — Evaluation of Endoscopic Management of Sinonasal Tumors In Difficult Anatomical Locations

StatusNot yet recruiting
PhaseN/A
SponsorAssiut University
Enrollment25
Study TypeINTERVENTIONAL
ConditionsNasal Cavity and Paranasal Sinus Cancer
Interventions

Research outcome measures:

  1. Primary (main):

    To Evaluate the Gross Total Resection Rate Using Endoscopic Approach for Lesions Extended To Anatomically Challenging Areas

  2. Secondary (subsidiary):

    1. Assess postoperative improvement in Quality of Life
    2. Quantify intraoperative blood loss and surgical duration
    3. Document the incidence of complications (CSF leak, nerve palsy, vas…

NCT07563075 — Effect of High-Flow Nasal Cannula Oxygen Therapy on Hypoxemia in Pediatric Sedated Bronchoscopy

StatusNot yet recruiting
PhaseN/A
SponsorZhejiang University
Enrollment430
Study TypeINTERVENTIONAL
ConditionsHypoxemia; Pneumonia; Pulmonary Neoplasm
Interventions;

Due to children’s lower oxygen reserves and higher oxygen consumption, sedation can easily lead to respiratory adverse events such as hypoxemia. It has been reported that the incidence of hypoxemia during pediatric bronchoscopy is high, highlighting that hypoxemia in pediatric painless bronchoscopy is an urgent problem requiring a solution. High-flow nasal cannula (HFNC) oxygen therapy delivers…

NCT07524894 — Staph Nasal Decolonization to Improve Function and Feeding

StatusNot yet recruiting
PhasePhase 2
SponsorDavid Palma
Enrollment126
Study TypeINTERVENTIONAL
ConditionsRadiation Mucositis; Staphylococcal Aureus Infection; Head and Neck Cancer
Interventions;

Radiation therapy is a type of treatment that involves using radiation beams targeted at a cancer to destroy the cancer cells or slow their growth. This type of treatment has helped many cancer patients for decades and is intended to kill cancer cells directly. Patients with head and neck cancer are commonly treated with radiation, sometimes after surgery and sometimes the radiation is delivere…

NCT07674030 — Functional and Aesthetic Comparison of Surgical Nasal Reconstruction Versus Nasal Prosthesis (Epithesis) After Total or Subtotal Nasal Amputation

StatusNot yet recruiting
PhaseN/A
SponsorHôpital NOVO
Enrollment20
Study TypeOBSERVATIONAL
ConditionsNose Cancer; Rhinectomy
Interventions

CERNAS is a prospective, multicenter, non-interventional study comparing the functional and aesthetic outcomes of two rehabilitation strategies after total or subtotal nasal amputation: surgical reconstruction (primarily paramedian forehead flap or free flap) versus nasal epithesis (prosthesis). Patients who have undergone either rehabilitation at least one year prior to enrolment will be invit…

NCT07667400 — Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

StatusNot yet recruiting
PhasePhase 1 / Phase 2
SponsorNational Cancer Institute (NCI)
Enrollment120
Study TypeINTERVENTIONAL
ConditionsHead and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Paranasal Sinus Neoplasms; Nasopharyngeal Carcinoma; Oropharyngeal Squamous Cell Carcinoma
Interventions;

Background:

Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States. Survival rates for these cancers are lower than 50% if they spread to other parts of the body or return after treatment. Better treatments are needed.

Objective:

To test…

NCT04181463 — Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients With Cancer

StatusNot yet recruiting
PhasePhase 2
SponsorM.D. Anderson Cancer Center
Enrollment112
Study TypeINTERVENTIONAL
ConditionsMalignant Neoplasm
Interventions; ;

The goal of this research study is to understand the effect of inhalation approaches in reducing nausea in cancer patients.

Completed Trials

NCT00003809 — Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

StatusCompleted
PhasePhase 3
SponsorEastern Cooperative Oncology Group
EnrollmentN/A
Study TypeINTERVENTIONAL
ConditionsHead and Neck Cancer
Interventions;

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether cisplatin plus monoclonal antibody therapy is more effective than cisplatin alone for metastatic or recurre…

NCT00939627 — Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

StatusCompleted
PhasePhase 2
SponsorNational Cancer Institute (NCI)
Enrollment55
Study TypeINTERVENTIONAL
ConditionsMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx
Interventions; ;

Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known…

NCT01384513 — A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

StatusCompleted
PhasePhase 2
SponsorSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Enrollment40
Study TypeINTERVENTIONAL
ConditionsAdult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Interventions; ;

This phase II trial studies how well reduced intensity donor stem cell transplant works in treating patients with hematologic malignancies. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient’s immune …

NCT02589938 — Trial of Acupuncture for Radiation-Induced Xerostomia in Head and Neck Cancer

StatusCompleted
PhaseN/A
SponsorWake Forest University Health Sciences
Enrollment258
Study TypeINTERVENTIONAL
ConditionsRadiation-Induced Xerostomia; Head and Neck Cancer; Radiation Toxicity; Oral Complications of Chemotherapy and Head/Neck Radiation
Interventions; ;

This study is being done to find out what effects, good and/or bad, acupuncture has on participants and their xerostomia caused by radiation therapy for the treatment of the cancer.

NCT02232516 — Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

StatusCompleted
PhasePhase 2
SponsorNorthwestern University
Enrollment30
Study TypeINTERVENTIONAL
ConditionsAdult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Hepatosplenic T-cell Lymphoma; Peripheral T-cell Lymphoma
Interventions; ;

The purpose of this study is to evaluate how safe and effective the combination of the study drugs romidepsin and lenalidomide is for treating patients with peripheral t-cell lymphoma (PTCL) who have not been previously treated for this cancer. Currently, there is no standard treatment for patients with PTCL; the most common treatment used is a combination of drugs called CHOP, but this can be …

NCT05199584 — A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

StatusCompleted
PhasePhase 2
SponsorEndeavor Biomedicines, Inc.
Enrollment20
Study TypeINTERVENTIONAL
ConditionsSolid Tumors With PTCH1 Loss-of-function Mutations
Interventions

This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF) mutations in the Patched-1 (PTCH1) gene. Stage 1 of this study will enroll approximately 44 patients randomized between two dose levels. As appropriate, Stage 2 of the st…

NCT07419113 — Development of an Integrated Multi-channel Artificial Nose for Cancer Detection (UNos)

StatusCompleted
PhaseN/A
SponsorInstitute of Oncology Ljubljana
Enrollment45
Study TypeINTERVENTIONAL
ConditionsHead and Neck Cancer
Interventions

This interventional diagnostic study evaluated a multi-channel artificial nose (UNos) medical device for analysis of exhaled breath in participants with head and neck squamous cell carcinoma and healthy volunteers. Participants underwent a standardized breath sampling procedure, and exhaled air was analyzed using semi-selective sensor arrays to generate quantitative breath pattern signatures. T…

Other (Withdrawn)

NCT05454163 — Post-radiotherapy Rhinosinusitis in Children

StatusWithdrawn
PhaseN/A
SponsorUniversity Hospital, Lille
EnrollmentN/A
Study TypeOBSERVATIONAL
ConditionsPediatric Cancer; Chronic Sinusitis
Interventions

Chronic rhinosinusitis (CRS) is a frequent complication of facial cancer treatment, mainly related to radiotherapy. However, while radiological involvement is frequent, clinical expression seems less important.

Few studies have investigated the incidence of this condition in the pediatric population while its evolution seems to be very chronic even if a partial improvement may occur with time….